Literature DB >> 10846081

Enhancement of primary and secondary cellular immune responses against human immunodeficiency virus type 1 gag by using DNA expression vectors that target Gag antigen to the secretory pathway.

J T Qiu1, B Liu, C Tian, G N Pavlakis, X F Yu.   

Abstract

In this study, we have investigated the influence of antigen targeting after DNA vaccination upon the induction of cellular immune responses against human immunodeficiency virus type 1 (HIV-1) Gag. In addition to the standard version of HIV-1 Gag, we constructed Gag expression vectors that encode a secreted (Sc-Gag) and a cytoplasmic (Cy-Gag) Gag molecule. Although all three HIV-1 Gag expression vectors induced detectable humoral and cellular immune responses, after intramuscular injection the DNA vector encoding the Sc-Gag generated the highest primary cytotoxic T-lymphocyte (CTL) and T-helper responses. Mice immunized with one of the HIV-1 Gag DNA vectors (but not with the control vector pcDNA3. 1) developed a protective immune response against infection with recombinant vaccinia virus expressing HIV-1 Gag, and this response persisted for 125 days. The magnitude of the protection correlated with the levels of Gag-specific ex vivo CTL activity and the number of CD8(+) T cells producing gamma interferon. The DNA vector encoding the Sc-Gag induced higher levels of protection and greater secondary CTL responses than did the DNA vector encoding Cy-Gag.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10846081      PMCID: PMC112096          DOI: 10.1128/jvi.74.13.5997-6005.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  In vivo priming by DNA injection occurs predominantly by antigen transfer.

Authors:  M Corr; A von Damm; D J Lee; H Tighe
Journal:  J Immunol       Date:  1999-11-01       Impact factor: 5.422

2.  Altering the cellular location of an antigen expressed by a DNA-based vaccine modulates the immune response.

Authors:  P J Lewis; L A Babiuk
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

3.  Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection.

Authors:  L Musey; J Hughes; T Schacker; T Shea; L Corey; M J McElrath
Journal:  N Engl J Med       Date:  1997-10-30       Impact factor: 91.245

4.  Differential dependence on target site tissue for gene gun and intramuscular DNA immunizations.

Authors:  C A Torres; A Iwasaki; B H Barber; H L Robinson
Journal:  J Immunol       Date:  1997-05-15       Impact factor: 5.422

Review 5.  DNA vaccines.

Authors:  J J Donnelly; J B Ulmer; J W Shiver; M A Liu
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

6.  Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation.

Authors:  R Schneider; M Campbell; G Nasioulas; B K Felber; G N Pavlakis
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

7.  Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia.

Authors:  E S Rosenberg; J M Billingsley; A M Caliendo; S L Boswell; P E Sax; S A Kalams; B D Walker
Journal:  Science       Date:  1997-11-21       Impact factor: 47.728

8.  Mutations in the matrix protein of human immunodeficiency virus type 1 inhibit surface expression and virion incorporation of viral envelope glycoproteins in CD4+ T lymphocytes.

Authors:  Y M Lee; X B Tang; L M Cimakasky; J E Hildreth; X F Yu
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

9.  Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by non-muscle cells.

Authors:  J B Ulmer; R R Deck; C M Dewitt; J I Donnhly; M A Liu
Journal:  Immunology       Date:  1996-09       Impact factor: 7.397

10.  Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice.

Authors:  S Lu; J C Santoro; D H Fuller; J R Haynes; H L Robinson
Journal:  Virology       Date:  1995-05-10       Impact factor: 3.616

View more
  22 in total

1.  Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines.

Authors:  Shixia Wang; Jessica Taaffe; Christopher Parker; Alicia Solórzano; Hong Cao; Adolfo García-Sastre; Shan Lu
Journal:  J Virol       Date:  2006-09-20       Impact factor: 5.103

2.  Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.

Authors:  Geoffrey W Stone; Suzanne Barzee; Victoria Snarsky; Kristin Kee; Celsa A Spina; Xiao-Fang Yu; Richard S Kornbluth
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

3.  Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice.

Authors:  Shih-Wen Lin; Scott E Hensley; Nia Tatsis; Marcio O Lasaro; Hildegund C J Ertl
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

4.  Post-translational intracellular trafficking determines the type of immune response elicited by DNA vaccines expressing Gag antigen of Human Immunodeficiency Virus Type 1 (HIV-1).

Authors:  Aaron Wallace; Kim West; Alan L Rothman; Francis A Ennis; Shan Lu; Shixia Wang
Journal:  Hum Vaccin Immunother       Date:  2013-08-13       Impact factor: 3.452

5.  Structure and immunogenicity of alternative forms of the simian immunodeficiency virus gag protein expressed using Venezuelan equine encephalitis virus replicon particles.

Authors:  Chad Cecil; Ande West; Martha Collier; Christy Jurgens; Victoria Madden; Alan Whitmore; Robert Johnston; Dominic T Moore; Ronald Swanstrom; Nancy L Davis
Journal:  Virology       Date:  2007-02-01       Impact factor: 3.616

6.  Comparative analysis of antigen-targeting sequences used in DNA vaccines.

Authors:  Joana A Carvalho; Adriano R Azzoni; Duarte M F Prazeres; Gabriel A Monteiro
Journal:  Mol Biotechnol       Date:  2010-03       Impact factor: 2.695

7.  DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.

Authors:  Sachin Gupta; Emily S Clark; James M Termini; Justin Boucher; Saravana Kanagavelu; Celia C LeBranche; Sakhi Abraham; David C Montefiori; Wasif N Khan; Geoffrey W Stone
Journal:  J Virol       Date:  2015-01-28       Impact factor: 5.103

8.  Conditioned Medium From Azurin-Expressing Human Mesenchymal Stromal Cells Demonstrates Antitumor Activity Against Breast and Lung Cancer Cell Lines.

Authors:  Marília Silva; Gabriel Amaro Monteiro; Arsenio M Fialho; Nuno Bernardes; Cláudia Lobato da Silva
Journal:  Front Cell Dev Biol       Date:  2020-07-09

Review 9.  Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production.

Authors:  James A Williams; Aaron E Carnes; Clague P Hodgson
Journal:  Biotechnol Adv       Date:  2009-02-20       Impact factor: 14.227

10.  Immunization of DNA vaccine encoding C3d-VP1 fusion enhanced protective immune response against foot-and-mouth disease virus.

Authors:  Huiying Fan; Tiezhu Tong; Huanchun Chen; Aizhen Guo
Journal:  Virus Genes       Date:  2007-05-12       Impact factor: 2.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.